Sitagliptin

Drug Profile

Sitagliptin

Alternative Names: Glactiv; Januvia; MK-0431; MK-431; ONO-5435; Tesavel; Xelevia

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co; Merck Sharp & Dohme
  • Developer Banyu; Merck & Co; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; University of Colorado at Denver; Washington University School of Medicine
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 07 Apr 2017 Merck receives complete response letter from the FDA for sitagliptin and it's combination treatment of patients with Type 2 diabetes mellitus
  • 28 Feb 2017 Merck has patent protection for sitagliptin in Europe and Japan (Merck Annual report 2016)
  • 01 Nov 2016 Merck completes a phase-III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (NCT02577016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top